Randomised Phase 3 Study of Rituximab in High-Risk Patients With Diffuse Large B-Cell Lymphoma Who Received a First-Line Consolidative Chemotherapy With Autologous Stem Cell Transplant (ASCT)

Trial Profile

Randomised Phase 3 Study of Rituximab in High-Risk Patients With Diffuse Large B-Cell Lymphoma Who Received a First-Line Consolidative Chemotherapy With Autologous Stem Cell Transplant (ASCT)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2012

At a glance

  • Drugs Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Etoposide; Folinic acid; Methotrexate; Mitoxantrone; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2010 Quality-of-life analysis presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Dec 2009 Primary endpoint 'Event free survival' has not been met.
    • 01 Dec 2009 Results reported in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top